Advances in pharmacotherapy of small cell lung cancer

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509

(2014) Miyako Satouchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study

(2013) Kaoru Kubota et al.   LANCET ONCOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

(2012) Jian-Mei Hou et al.   JOURNAL OF CLINICAL ONCOLOGY

Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial

(2012) Thomas H. Fink et al.   Journal of Thoracic Oncology

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

(2012) Ji-Youn Han et al.   LUNG CANCER

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

(2012) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

(2011) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies

(2011) Beate Pesch et al.   INTERNATIONAL JOURNAL OF CANCER

Reply to M. Buyse et al

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

(2011) Bryan J. Schneider et al.   Journal of Thoracic Oncology

A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer

(2011) Maria Q. Baggstrom et al.   Journal of Thoracic Oncology

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

(2011) Paul K. Paik et al.   LUNG CANCER

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

(2010) P. Zatloukal et al.   ANNALS OF ONCOLOGY

Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-Kit–Positive, Extensive-Stage Small-Cell Lung Cancer

(2010) Bryan J. Schneider et al.   Clinical Lung Cancer

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

(2010) David S. Ettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

(2010) Robert Jotte et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)

(2010) Antonius A. Miller et al.   Journal of Thoracic Oncology

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer

(2010) Jingwei Jiang et al.   Journal of Thoracic Oncology

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)

(2010) Gregory A. Otterson et al.   Journal of Thoracic Oncology

Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

(2010) João Paulo S.N. Lima et al.   Journal of Thoracic Oncology

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

(2010) Barbara J. Gitlitz et al.   Journal of Thoracic Oncology

Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis

(2010) Antonio Rossi et al.   LUNG CANCER

Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer

(2009) Tsuneo Shimokawa et al.   International Journal of Clinical Oncology

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer

(2009) Bryan J. Schneider et al.   INVESTIGATIONAL NEW DRUGS

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

(2009) Siow Ming Lee et al.   JNCI-Journal of the National Cancer Institute

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

(2008) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY

A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial

(2008) S. Leyvraz et al.   JNCI-Journal of the National Cancer Institute